Antibodies in human infectious disease

被引:0
作者
Paul W. H. I. Parren
Pascal Poignard
Henrick J. Ditzel
R. Anthony Williamson
Dennis R. Burton
机构
[1] The Scripps Research Institute,Department of Immunology
来源
Immunologic Research | 2000年 / 21卷
关键词
Infectious disease; Pathogenesis; Antibody response; Vaccines; Human immunodeficiency virus type 1; Ebola virus; Respiratory syncytial virus; Prion;
D O I
暂无
中图分类号
学科分类号
摘要
Investigation of human antibody responses to viral pathogens at the molecular level is revealing novel aspects of the interplay of viruses with the humoral immune system. In viral infection, at least two types of human antibody responses exist: a response to mature envelope on virions that is neutralizing and a response to immature forms of envelope (viral debris) that is not. Many pathogens have, to varying degrees, evolved envelopes to minimize antibody responses against epitopes exposed on the viron. In this article, we review recent studies on human immunodeficiency virus type 1, Ebola virus, and respiratory syncytial virus. Prion diseases are diseases of protein conformation. We have generated a large panel of antibodies recognizing the cellular prion protein (PrPc), some of which also react with the abnormally folded infectious prion protein (PrPSc). These antibodies are being used to gain insight into both the molecular events leading to the formation of infectious PrP and the physiologic role played by PrP in normal and prion-infected cells.
引用
收藏
页码:265 / 278
页数:13
相关论文
共 304 条
[31]  
Burton DR(1997)Protectionagainst HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site Nat Med 3 1389-1393
[32]  
Pyati J(1999)Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1 J Virol 73 4009-4018
[33]  
Koduri R(1998)Protection of macaques against pathogenic SHIV-89.6PD by passive transfer of neutralizing antibodies AIDS Res Hum Retroviruses 14 1035-1043
[34]  
Burton DR(1999)Neutralizing antibodies administered before, but not after, virulent SHIV prevent infection in macaques Nat Med 5 189-193
[35]  
Barbas CF(1999)Requirement for multiple lymphocyte subsets in protection against retroviral infection by a live-attenuated vaccine Immunity 10 1-20
[36]  
Persson MAA(1998)Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo J Virol 72 10,270-10,274
[37]  
Koenig S(1997)Antibody neutralization-resistant primary isolates of human immunodeficiency virus type-1 J Virol 71 6869-6874
[38]  
Chanock RM(1992)Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1 b12 Proc Natl Acad Sci USA 89 10,164-10,168
[39]  
Lerner RA(1994)Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity Proc Natl Acad Sci USA 91 1386-1390
[40]  
Ditzel HJ(1999)Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice J Virol 65 18-56